Physician profile
John E Conrey
NPI 1114978715
$2,913.36
in general payments reported to CMS, 2019-2025
27 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $11.76 · 2021: $258 · 2022: $261 · 2023: $368 · 2024: $813 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $343.83 | 2023-2025 | Gore Excluder Aaa Endoprosthesis, Excluder Conformable Aaa Endoprosthesis With Active Control |
| Novartis Pharmaceuticals Corporation | $324.13 | 2020-2025 | |
| Penumbra, INC. | $304.71 | 2021-2025 | Indigo System |
| Astrazeneca Pharmaceuticals Lp | $229.79 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $216.97 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $204.82 | 2021-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.92 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $180.62 | 2022-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $131.06 | 2024-2025 | Jynarque, Voyxact |
| Endologix LLC | $119.35 | 2021 | |
| Calliditas Therapeutics US INC. | $102.41 | 2025 | Tarpeyo |
| Lilly USA, LLC | $82.39 | 2023-2024 | Jardiance |
| Scpharmaceuticals INC. | $67.19 | 2025 | |
| Apellis Pharmaceuticals, INC. | $64.46 | 2025 | Empaveli |
| Opko Pharmaceuticals, LLC | $40.45 | 2022-2024 | Rayaldee |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $34.43 | 2019 | |
| Amgen INC. | $31.61 | 2022-2024 | Tavneos |
| Akebia Therapeutics INC | $29.46 | 2025 | Vafseo |
| Aurinia Pharma U.S., INC. | $28.53 | 2022 | |
| Nxstage Medical, INC. | $28.18 | 2023 | Nxstage System One |
| Fresenius USA Marketing, INC. | $27.05 | 2019 | |
| Abbott Laboratories | $24.88 | 2019 | |
| Pharmacosmos Therapeutics INC. | $24.34 | 2024 | Monoferric |
| Ardelyx, INC. | $23.17 | 2025 | Ibsrela |
| Glaxosmithkline, LLC. | $22.40 | 2023 | Jesduvroq |
| Horizon Therapeutics Plc | $19.66 | 2022 | |
| Mallinckrodt Enterprises LLC | $19.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Conrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.